Prolonged Response to Nivolumab in Metastatic Melanoma
Results of a phase 1 trial may raise expectations for better outcomes with lower toxicity.
{{{error}}}
{{error}}
{{{ form.title }}}
*Required
{{{field.value}}}
{{{field.value}}}
{{{field.value}}}
